DaZhu Rhodiola Rosea Capsule for Coronary Artery Disease With Angina Pectoris

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 102 participants.

Also called NCT03633890

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 102 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT03633890
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT03633890. Randomized; double masking; primary purpose treatment. Start 2018-08 (anticipated); primary completion 2019-02 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
DaZhu Rhodiola Rosea Capsule for Coronary Artery Disease With Angina Pectoris
Intervention (Drug)
DaZhu Rhodiola Rosea Capsule
Intervention (Drug)
DaZhu Rhodiola Rosea Simulation Capsule
Lead sponsor
Beijing Anzhen Hospital (class: other)
Collaborator
Jiangsu Kangyuan Pharmaceutical Co. Ltd (class: not stated)

Record details

Record id
cardio:ct-nct03633890
Content hash
97ead849aef84c102c65a5d7976a197f9723e58a9ac83d6fd5fab89d45014f9d